Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Sign Up to like & getrecommendations! Published in 2017 at "Dermatology and Therapy"
DOI: 10.1007/s13555-017-0201-6
Abstract: IntroductionDupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has… read more here.
Keywords: dupilumab; treatment moderate; cost; moderate severe ... See more keywords
Abrocitinib: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01638-3
Abstract: Abrocitinib (Cibinqo®) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD). In September 2021, abrocitinib was approved in the UK and Japan… read more here.
Keywords: first approval; treatment moderate; abrocitinib; moderate severe ... See more keywords
Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000014042
Abstract: Background: Secukinumab has been approved for the treatment of moderate to severe plaque psoriasis. However, safety measures concerning drug administration is vital during treatment. Understanding the right way to administer drugs is important to reduce… read more here.
Keywords: severe plaque; treatment; drug; treatment moderate ... See more keywords
Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031527
Abstract: Psoriasis is a disease of immunological origin that damages the skin and mucous membranes. Biological therapies with systemic medications are effective in treating moderate and severe psoriasis. Our objective was to evaluate the effects of… read more here.
Keywords: moderate severe; treatment; severe psoriasis; psoriasis ... See more keywords
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in a solid organ transplanted recipient: A case report
Sign Up to like & getrecommendations! Published in 2021 at "Australasian Journal of Dermatology"
DOI: 10.1111/ajd.13568
Abstract: Psoriasis is an autoimmune T cell-mediated disease with a mean prevalence in Europe and North America of about 2%. In recent years, a better understanding of its immunepathogenesis has led to the improvement of drug… read more here.
Keywords: dermatology; treatment; case; treatment moderate ... See more keywords
Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study *
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20827
Abstract: Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to‐severe plaque psoriasis. Maintenance dosing every 4 weeks is well established with IL‐17 inhibitors for… read more here.
Keywords: severe plaque; plaque psoriasis; treatment moderate; moderate severe ... See more keywords
Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cosmetic Dermatology"
DOI: 10.1111/jocd.14906
Abstract: Previous studies indicate that the efficacy and durability of a single AbobotulinumtoxinA (ABO) treatment for moderate to severe glabellar lines may be enhanced with increasing dose, while safety outcomes remain consistent with those of the… read more here.
Keywords: moderate severe; severe glabellar; treatment moderate; glabellar lines ... See more keywords
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Pharmacotherapy"
DOI: 10.1177/1060028019885836
Abstract: Objective: Risankizumab (Skyrizi), an interleukin-23 (IL-23) antagonist, was approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in April 2019. This article will review phase II and… read more here.
Keywords: psoriasis; treatment moderate; risankizumab; plaque psoriasis ... See more keywords
A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis.
Sign Up to like & getrecommendations! Published in 2017 at "Immunotherapy"
DOI: 10.2217/imt-2017-0077
Abstract: Psoriasis is a chronic immune-mediated skin disorder affecting approximately 2-3% of the worldwide population. Recent advances in our understanding of the immunopathogenesis of psoriasis have resulted in novel therapeutic agents. IL-17, a pro-inflammatory cytokine, plays… read more here.
Keywords: psoriasis; treatment moderate; moderate severe; severe plaque ... See more keywords
From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10102620
Abstract: Complex immune response to infection has been highlighted, more than ever, during the COVID-19 pandemic. This review explores the immunomodulatory treatment of moderate-to-severe forms of this viral sepsis in the context of specific immunopathogenesis. Our… read more here.
Keywords: immunomodulatory treatment; cytokine; covid; moderate severe ... See more keywords